Connection

Chadrick Denlinger to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Chadrick Denlinger has written about Dose-Response Relationship, Drug.
Chadrick Denlinger
Connection Strength
0.023
Dose-Response Relationship, Drug
  1. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan; 75(1):17-23.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.